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Dyskerin, telomerase and the DNA damage response
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The Genetics of Dyskeratosis Congenita
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Dyskeratosis congenita is genetically diverse with autosomal recessive and dominant and X-linked pedigrees having been described
(Table 1). The major X-linked form is due to mutations in the
DKC1 gene which encodes the 57 kD protein dyskerin.4 Dyskerin
is a highly conserved nucleolar protein that, as part of a specialized
nucleolar RNP, catalyses the pseudouridylation of specific residues
in newly synthesized ribosomal RNAs and spliceosomal snRNAs.5
Dyskerin also associates with telomerase,6 and since products of 4
other genes whose mutation causes DC also associate with telomerase
it is thought that telomerase defects underlie the DC phenotype.
These other genes are NOP10,7 NHP2 (recessive),8 TERC9 and
TERT10 (dominant). NOP10 and NHP2 are associated with dyskerin in both the RNP complex and in telomerase while TERC is the
telomerase RNA template and TERT is the telomerase reverse transcriptase. A sixth gene causing DC, TINF2,11,12 encodes a protein
TIN2,13 that is not part of telomerase but is one of the protein
components of shelterin, a protein complex associated with telomere
DNA at the ends of chromosomes.14
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The bone marrow failure syndrome Dyskeratosis congenita
(DC), though rare, has attracted a great deal of attention in the
last few years because it is caused by mutations in genes whose
products are involved in telomere maintenance. The disease
presents with a variety of features that can all be due to failure
of tissues that require constant renewal via stem cell activity. It is
thought this is caused by defects in telomere maintenance leading
eventually to cell cycle arrest or cell death caused by critically short
telomeres. The most common form of DC is the X-linked form
caused by mutations in DKC1 encoding the nucleolar protein,
dyskerin. We recently reported a mouse model of the X-linked
form of the disease in which females heterozygous for a mutation that copies a human pathogenic mutation showed a growth
disadvantage in cells expressing the mutant dyskerin. This growth
disadvantage, which was associated with an enhanced DNA
damage response, was dependent on telomerase but appeared to
be independent of telomere shortening. Here we discuss these
results in terms of the role of dyskerin in telomere maintenance
and the possible role that the DNA damage response plays in the
pathogenesis of DC.
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Telomere homeostasis is important in cancer, where nearly
all tumors require increased levels of telomerase to counteract
the telomere shortening that takes place with each cell division.1
Telomere maintenance may also be important in aging, since
telomere shortening in somatic cells, which express no or little telomerase, means that these cells have a finite number of cell divisions
before critically short telomeres drive the cells into senescence in a
process known as replicative aging.2,3 The role of telomere shortening in organismal aging is controversial. In dyskeratosis congenita
we have the opportunity to observe the effects of defective telomere
maintenance in humans, and the role of telomere maintenance in
cancer and aging.
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Molecular Pathology
Dyskeratosis congenita, though classically defined by a triad of
mucocutaneous features (skin pigmentation abnormalities, leukoplakia and nail dystrophy) usually involves bone marrow failure
which is often the cause of death. It is always associated with very
short telomeres that are shorter than the first percentile of telomere
lengths seen in the normal population.15 DC mutations have also
been found in patients with aplastic anemia16 and pulmonary
fibrosis17,18 leading to a less restricted definition of the disease.
Expression of the disease, which correlates to some extent with the
gene mutation, (Table 1) varies between very severe presentation in
children below 1 to mild anemia in old age. It is generally accepted
that the defects in DC are caused by increased rates of telomere
shortening in adult stem cells leading to failure of cell renewal and
thereby causing bone marrow failure, pulmonary fibrosis and the
other manifestations of DC, which include an increased susceptibility to cancer. In X-linked DC there is good evidence that
the mutations in dyskerin lead to destabilization of TERC and a
decrease in telomerase activity.19 In this X-linked condition female
carriers of the disease usually show 100% skewing of X-inactivation,
at least in white blood cells.20,21 At an early stage of embryonic
development in female placental mammals one X-chromosome is
inactivated in every cell. It is random whether in any given cell the

Cell Cycle

2009; Vol. 8 Issue 1
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Table 1 Characteristics of genes mutated in dyskeratosis congenita
Types of mutation

Clinical presentation

References

X-linked recessive.
Dyskeratosis congenita (DC)
varying in severity.
The more severe variant
Hoyeraal-Hreidarrson syndrome
(HH) characterized by
intra-uterine growth
retardation, immune deficiency
and cerebellar hypoplasia.

4, 45

Autosomal dominant.
Usually sporadic.
DC, HH, AA and Revesz
syndrome, severe bone
marrow failure with
retinopathy. Nearly
always severe.

11, 12

Telomerase RNA
3q21-q28
RNA component of
All types, deletions,
component		
telomerase—provides
point mutations etc.
			
template for synthesis of		
			
telomere repeats		
					

Autosomal dominant.
Wide variety of presentation
including DC, aplastic anemia,
pulmonary fibrosis, MDS.
Variable penetrance.

16–18,
45, 46

TERT

Autosomal dominant.
Rarely autosomal recessive.
Wide variety of presentation
including DC, aplastic anemia,
pulmonary fibrosis, MDS.
Variable penetrance.

10, 17,
18, 43,
45,
47–49

Autosomal recessive.
Mild dyskeratosis congenita,
low penetrance of
aplastic anemia.

7

Autosomal recessive.
Both patients had
classical dyskeratosis
congenita

8

TIN2—TRF1 interacting
14q12
Component of shelterin
factor 2		
complex at telomeres
				
				
				
				
				

Mainly missense
clustered at aa
280–291 with
two thirds
affecting
residue 282.
Some frameshifts.

T

TINF2
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DKC1
Dyskerin
Xq28
Pseudouridine synthase.
Mainly mis-sense.
			
Component of H/ACA
Common recurrent
			
RNP and telomerase
mutation 40% of
			
complex
X-linked cases is A353V.
				
Null mutations
				
probably lethal
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Telomerase reverse
5p15.33
Telomerase reverse
All types, deletions,
transcriptase		
transcriptase—synthesizes
point mutations etc.
			
telomere repeats		
					
					
					

NOP10—Nucleolar 15q14-q15 Component of H/ACA
1 missense mutation described
protein 10		
RNP and telomerase
in 1 family with 3
			
complex
homozygous affected siblings
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NOP10

NHP2—Non-histone
Chr 5
Component of H/ACA
chromosome protein 2		
RNP and telomerase
			
complex
				
				
				

2 patients have been
described—1 homozygous
for a missense mutation and the
other compound heterozygous
for a missense and
a nonsense mutation.
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paternal or maternal X is inactivated.22,23 Thereafter in carriers of
a DKC1 mutation there will be 2 types of cell, one with wild type
and one with mutant dyskerin, and cells with wild type dyskerin
must outgrow those with mutant dyskerin leading to only one type
of cell in the adult.
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A Mouse Model of X-linked DC
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We have made a mouse model of X-linked DC24 by recreating
in the mouse a mutation that causes DC in an X-linked family,25 a
deletion of exon 15 that leads to a truncation of the dyskerin protein
by 22 amino acids in human and 21 amino acids in mouse. This
deletion had the advantage that we were able to distinguish between
the wild type and mutant protein on Western blots. Male mice
carrying the deletion, Dkc1D15, did not show any obvious phenotype
but in female heterozygous mice, Dkc1D15/+, expression of the two
proteins was unequal in older mice with greater expression of the
wild type protein. We reasoned that this was most likely due to a
growth advantage enjoyed by the cells expressing wild type dyskerin
after random X-inactivation. This was supported by the fact that
www.landesbioscience.com
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Gene
Gene product
		

the differences in expression at the protein level were reflected in
differences in mRNA levels. The growth advantage was greater in
hematopoietic tissues such as spleen and bone marrow but was also
evident in less proliferative tissues such as liver. Part of the rationale
for our experimental approach was that mice would not be expected
to show any phenotype due to telomere shortening in the first generation. This was based on the observations that mice that are null
for telomerase RNA, (Terc-/-)26 or telomerase reverse transcriptase
(Tert-/-)27 do not show a phenotype at first but after inbreeding for
several generations show a phenotype with similarities to human
DC. This is because laboratory mice have very long telomeres and
several generations in the absence of telomerase are required before
telomeres reach a critically short length. Surprisingly, however, when
we tested Dkc1D15/+Terc-/- or Dkc1D15/+Tert-/- mice no growth advantage was evident. The growth advantage was also partially rescued in
Dkc1D15/+p53-/- mice. Together these results suggested that cells with
the Dkc1D15 mutation exhibit slower growth than wild type cells and
that this was dependent on telomerase, was independent of telomere
length and was mediated, at least in part via p53.
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Telomere maintenance and the DNA damage response are closely
connected with many of the proteins involved in the DNA damage
response also playing important roles in telomere maintenance.29 It
is well known that critically short telomeres induce a p53 dependent
DNA damage response that, if unresolved, may lead to cell cycle
arrest and senescence or apoptosis.30 Indeed the accepted view of
the pathogenesis of DC is that defects in telomerase lead to accelerated telomere shortening and eventually to short telomere induced
senescence/apoptosis in stem cells. As well as telomere length defective telomere structure may also cause a DNA damage response.31
Moreover a transient DNA damage response is thought to occur at
telomeres during replication.32 Since telomere elongation and replication are presumably tightly coupled33 it is likely that defects in
elongation may enhance this response. Although dyskerin is thought
to be involved chiefly in the assembly of the functional telomerase
complex its presence in purified active telomerase34 may suggest it
plays an important role in telomerase action. On this model mutant
dyskerin may affect the access of telomerase to its substrate or the efficiency of telomerase activity and lead to a dysfunctional telomere.
Another possibility is that telomerase has a cellular function not
dependent on telomere length and it is this function that is affected by
mutant dyskerin, leading to the DNA damage response. Suggestions
that telomerase has a telomere length independent function in
mice arise from observations that overexpression of telomerase can
promote tumorigenesis in mice with perfectly long telomeres35,36 and
conversely that lack of telomerase can suppress chemically induced
carcinogenesis in long telomere mice.37 In addition in human cells
hTERT was shown to contribute to tumorigenesis in the absence of
any effect on telomere length maintenance.38 The mechanism of this
length independent role of telomerase and its connection with DNA
damage at telomeres remains to be determined.
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Dyskerin and Telomerase in the DNA Damage Response
Pathway?

RI

The involvement of p53 in the reduced growth of cells with a
mutant dyskerin implicates a DNA damage responsive cell cycle
checkpoint in the phenomenon and indeed male Dkc1D15 MEF cells
were shown to have an enhanced DNA damage response following
etoposide treatment. Both wild type and mutant cells showed an
increase in DNA damage foci containing g-H2AX, a phosphorylated
histone that appears rapidly at sites of DNA damage,28 especially
double stranded breaks. Furthermore many of the DNA damage foci
co-localized with telomeres in the mutant but not the wild type cells.
These findings, implicating a hitherto unknown pathway, raise
many new questions, in particular:- What is the role of dyskerin and
telomerase in the DNA damage response? Is the reduction in growth
and increased DNA damage response important in the pathogenesis
of X-linked DC?

DC like phenotype was observed in male mice suggesting that the
lower proliferation rate is not sufficient to impact on tissue renewal,
at least in one generation. The assay we use to assess comparative
proliferation rate, namely competitive growth of cells in a female
mosaic after random X-inactivation may be very sensitive. Indeed if
32 cell divisions are required for the growth39 of an early embryo into
an adult mouse then a 5% increase in the time between cell divisions
will lead to an approximately 80% reduction in the number of the
slower growing cells. Such a small reduction in growth rate, while
easy to see in the competitive situation, may not affect the growth
and development of males. Another factor here may be differences
between mouse and humans in the detailed mechanisms of both
telomere maintenance40,41 and stem cell function.
Of the six genes so far identified as causing DC, two of them—
NOP107 and NHP28— have been found to be very rare and present
in one or a handful of families. The others fall into two groups
in terms of presentation and penetrance. Mutations in TERT 10
and TERC15 have less than 100% penetrance and generally show
anticipation with increased severity and earlier age of onset in later
generations.42,43 This is likely due to the fact that later generations
inherit shortened telomeres from the affected parent as well as
the pathogenic mutation. Mutations in DKC1,4 and TINF2,11,12
however exert their effects in generation 1 where they usually cause
severe aplastic anemia and dyskeratosis congenita of varying severity,
with TINF2 mutations perhaps being on average more severe. The
difference between these two groups may be that TERC and TERT
mutations lead to telomere shortening with no consequences until a
critically short telomere length is reached whereas DKC1 and TINF2
mutations in addition cause cell death via the p53 DNA damage
pathway due to telomere defects independent of telomere length
and thus exert their effects in generation 1. Supporting this idea is
our finding of a DNA damage response in mice with a pathogenic
Dkc1 mutation.24 While the TINF2 pathogenic mutations have not
yet been shown to elicit a DNA damage response at telomeres other
TIN2 mutations, that destabilize shelterin components TRF1 and
TRF2 do induce DNA damage.44 All DC patients however have
very short telomeres but whether short telomeres are always causative
of the disease or are a consequence of increased replicative telomere
erosion is not clear. Thus it is possible that the DNA damage caused
by these mutations contributes to bone marrow failure by leading
to increased rate of recruitment of stem cells and eventual stem cell
exhaustion (Fig. 1).
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Mutant Dyskerin Affects the DNA Damage Response
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Possible Importance of the DNA Damage Response in the
Pathogenesis of X-Linked DC
Is the induction of the DNA damage response an important
factor in the pathogenesis of dyskeratosis congenita? In the Dkc1D15/+
heterozygous female mice the induction of the DNA damage
response was associated with decreased proliferation. However no
8

Summary and Future Prospects
In summary the finding of an increased DNA damage response
in mice with a pathogenic mutation in Dkc1 has important implications for the role of dyskerin in telomere maintenance. Coupled with
the recent finding of DC due to TINF2 mutations it suggests that
failure to maintain telomere integrity in DC may arise by more than
one pathway. It will now be important to work out precisely how
dyskerin and TIN2 interact with other components of telomerase
and of shelterin to bring about the exquisite control of telomere
homeostasis needed to strike the essential balance between aging and
malignancy.
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Figure 1. Model of pathogenesis of dyskeratosis congenita.
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